Physician profile
Jose Cantu
NPI 1366627523
$42,419.79
in general payments reported to CMS, 2019-2025
43 companies · $3,119 in 2025
The $3,119 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $9,543 · 2021: $2,932 · 2022: $3,360 · 2023: $4,209 · 2024: $3,604 · 2025: $3,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $482 · Consulting Fee: $200 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,088.69 |
| Travel and Lodging | $482.38 |
| Consulting Fee | $200.00 |
| Education | $161.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $13,779.36 | 2019-2024 | Yupelri |
| Insmed, INC. | $9,715.44 | 2019-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $3,906.03 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,971.49 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,341.09 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,248.58 | 2019-2024 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Actelion Pharmaceuticals US, INC. | $1,148.09 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Electromed, INC. | $820.40 | 2021-2024 | Smartvest |
| Genzyme Corporation | $680.80 | 2019-2025 | |
| Harmony Biosciences LLC | $656.23 | 2020-2025 | Wakix |
| Grifols USA, LLC | $600.78 | 2020-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $579.01 | 2019-2025 | |
| Inspire Medical Systems, INC. | $559.53 | 2022-2025 | Inspire |
| Cook Incorporated | $482.38 | 2023 | Melker |
| Philips North America LLC | $459.90 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, Incourage Airway Clearance Therapy |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $458.84 | 2021-2025 | Acthar |
| Sunovion Pharmaceuticals INC. | $346.14 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $332.43 | 2023-2025 | Lumryz |
| Abbvie INC. | $287.70 | 2021-2025 | Teflaro, Avycaz |
| Abbott Laboratories | $282.50 | 2021-2024 | Advisor |
| Amgen INC. | $279.89 | 2022-2025 | Tezspire, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $241.77 | 2019-2024 | |
| Viatris Specialty LLC | $149.06 | 2025 | Yupelri |
| Pulmonx Corporation | $146.52 | 2023 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Shionogi INC | $105.05 | 2020-2021 | |
| Boston Scientific Corporation | $88.55 | 2020 | |
| Ani Pharmaceuticals, INC. | $74.95 | 2023-2024 | Purified Cortrophin Gel |
| Allergan, INC. | $73.13 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.34 | 2021 | |
| Verona Pharma, INC. | $70.66 | 2025 | Ohtuvayre |
| Circassia INC. | $62.45 | 2019-2020 | |
| United Therapeutics Corporation | $58.20 | 2021-2025 | Tyvaso, Tyvaso |
| Inogen, INC. | $48.13 | 2025 | |
| Itamar Medical INC | $46.32 | 2021-2022 | |
| Medtronic, INC. | $40.25 | 2024 | Illumisite |
| Lilly USA, LLC | $39.73 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $38.73 | 2023-2025 | Winrevair |
| Gilead Sciences, INC. | $28.09 | 2019-2021 | |
| Baxter Healthcare | $24.03 | 2022 | |
| 3b Medical, INC. | $22.34 | 2023 | Luna |
| Veran Medical Technologies, INC. | $20.67 | 2020 | |
| Genentech USA, INC. | $16.35 | 2020 | |
| Ethicon INC. | $15.86 | 2024 | Monarch Platform |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Cantu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.